Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2024

被引:412
作者
ElSayed, Nuha A.
Aleppo, Grazia
Bannuru, Raveendhara R.
Bruemmer, Dennis
Collins, Billy S.
Ekhlaspour, Laya
Gaglia, Jason L.
Hilliard, Marisa E.
Johnson, Eric L.
Khunti, Kamlesh
Lingvay, Ildiko
Matfin, Glenn
McCoy, Rozalina G.
Perry, Mary Lou
Pilla, Scott J.
Polsky, Sarit
Prahalad, Priya
Pratley, Richard E.
Segal, Alissa R.
Seley, Jane Jeffrie
Stanton, Robert C.
Gabbay, Robert A.
Beverly, Elizabeth A.
Cusi, Kenneth
Darville, Audrey
Das, Sandeep R.
Fleming, Talya K.
Gaglia, Jason L.
Galindo, Rodolfo J.
Gibbons, Christopher H.
Giurini, John M.
Hassanein, Mohamed
Kosiborod, Mikhail N.
Kushner, Robert F.
Murdock, Lisa
Napoli, Nicola
Selvin, Elizabeth
Silva, Paolo S.
Verduzco-Gutierrez, Monica
Woodward, Crystal C.
Younossi, Zobair M.
Pekas, Elizabeth J.
Yacoubian, Alexandra M.
机构
关键词
TYPE-2; DIABETES-MELLITUS; INITIAL COMBINATION THERAPY; MULTIPLE DAILY INJECTIONS; REGULAR U-500 INSULIN; BASAL-BOLUS REGIMEN; HYBRID CLOSED-LOOP; SEVERE HYPOGLYCEMIA; OPEN-LABEL; TECHNOSPHERE INSULIN; WEEKLY EXENATIDE;
D O I
10.2337/dc24-S009
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The American Diabetes Association (ADA) "Standards of Care in Diabetes" includes the ADA's current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, an interprofessional expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA's clinical practice recommendations and a full list of Professional Practice Committee members, please refer to Introduction and Methodology. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
引用
收藏
页码:S158 / S178
页数:21
相关论文
共 152 条
[1]   A meta-analysis comparing clinical effects of short- or long-acting GLP-1 receptor agonists versus insulin treatment from head-to-head studies in type 2 diabetic patients [J].
Abd El Aziz, Mirna S. ;
Kahle, Melanie ;
Meier, Juris J. ;
Nauck, Michael A. .
DIABETES OBESITY & METABOLISM, 2017, 19 (02) :216-227
[2]   Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT): a randomized trial [J].
Abdul-Ghani, M. A. ;
Puckett, C. ;
Triplitt, C. ;
Maggs, D. ;
Adams, J. ;
Cersosimo, E. ;
DeFronzo, R. A. .
DIABETES OBESITY & METABOLISM, 2015, 17 (03) :268-275
[3]   Efficacy and Safety of Liraglutide Added to Capped Insulin Treatment in Subjects With Type 1 Diabetes: The ADJUNCT TWO Randomized Trial [J].
Ahren, Bo ;
Hirsch, Irl B. ;
Pieber, Thomas R. ;
Mathieu, Chantal ;
Gomez-Peralta, Fernando ;
Hansen, Troels Krarup ;
Philotheou, Areti ;
Birch, Sune ;
Christiansen, Erik ;
Jensen, Thomas Jon ;
Buse, John B. .
DIABETES CARE, 2016, 39 (10) :1693-1701
[4]   Improved Postprandial Glucose with Inhaled Technosphere Insulin Compared with Insulin Aspart in Patients with Type 1 Diabetes on Multiple Daily Injections: The STAT Study [J].
Akturk, Halis Kaan ;
Snell-Bergeon, Janet K. ;
Rewers, Amanda ;
Klaff, Leslie J. ;
Bode, Bruce W. ;
Peters, Anne L. ;
Bailey, Timothy S. ;
Garg, Satish K. .
DIABETES TECHNOLOGY & THERAPEUTICS, 2018, 20 (10) :639-647
[5]   Efficacy of insulin dosing algorithms for high-fat high-protein mixed meals to control postprandial glycemic excursions in people living with type 1 diabetes: A systematic review and meta-analysis [J].
Al Balwi, Rana ;
Al Madani, Wedad ;
Al Ghamdi, Amal .
PEDIATRIC DIABETES, 2022, 23 (08) :1635-1646
[6]  
Aleppo G, 2017, J ENDOCR SOC, V1, P1445, DOI 10.1210/js.2017-00388
[7]   Training in flexible, intensive insulin management to enable dietary freedom in people with type 1 diabetes: dose adjustment for normal eating (DAFNE) randomised controlled trial [J].
Amiel, S ;
Beveridge, S ;
Bradley, C ;
Gianfrancesco, C ;
Heller, S ;
James, P ;
McKeown, N ;
Newton, D ;
Newton, L ;
Oliver, L ;
Reid, H ;
Roberts, S ;
Robson, S ;
Rollingson, J ;
Scott, V ;
Speight, J ;
Taylor, C ;
Thompson, G ;
Turner, E ;
Wright, F .
BRITISH MEDICAL JOURNAL, 2002, 325 (7367) :746-749
[8]  
[Anonymous], 2017, FDA Drug Safety Communication: FDA review results in new warnings about using general anesthetics and sedation drugs in young children and pregnant women
[9]   Durability of insulin degludec plus liraglutide versus insulin glargine U100 as initial injectable therapy in type 2 diabetes (DUAL VIII): a multicentre, open-label, phase 3b, randomised controlled trial [J].
Aroda, Vanita R. ;
Gonzalez-Galvez, Guillermo ;
Gron, Randi ;
Halladin, Natalie ;
Haluzik, Martin ;
Jermendy, Gyorgy ;
Kok, Adri ;
Orsy, Petra ;
Sabbah, Mohamed ;
Sesti, Giorgio ;
Silver, Robert .
LANCET DIABETES & ENDOCRINOLOGY, 2019, 7 (08) :596-605
[10]   Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial [J].
Aroda, Vanita R. ;
Bain, Stephen C. ;
Cariou, Bertrand ;
Piletic, Milivoj ;
Rose, Ludger ;
Axelsen, Mads ;
Rowe, Everton ;
DeVries, J. Hans .
LANCET DIABETES & ENDOCRINOLOGY, 2017, 5 (05) :355-366